Related Experiment Video
Updated: Jan 20, 2026

Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens
Published on: February 4, 2014
Solid cancer: the new tumour spread endpoint opens novel opportunities
Michael Fernandes1, Daniel Rosel2, Jan Brábek3
1Medbase, 114 Milton Avenue, Chapel Hill, NC, 27514, USA.
Abstract:
Novel androgen deprivation agents delay metastasis in non-metastatic, castration-resistant, prostate cancer (nmCRPC). The recent regulatory guidance: considerations for metastasis-free survival endpoint in clinical trials, opens new opportunities in cell biology, medicinal chemistry and advanced imaging. Past failures are the likely result of equating tumour shrinkage to efficacy, rather than inhibition of tumour spread. In the future, the selection of anti-metastasis drug candidates will probably be based on anti-migratory rather than anti-proliferative potential. Oligometastatic cancer coupled with advanced imaging can serve as a clinical proof-of-concept model.
Insights
New androgen deprivation therapies can delay cancer spread in non-metastatic, castration-resistant prostate cancer (nmCRPC). Future drug development will prioritize inhibiting tumor cell migration over proliferation for improved metastasis-free survival.
Area of Science:
- Oncology
- Cell Biology
- Medicinal Chemistry
Background:
- Novel androgen deprivation agents show promise in delaying metastasis for non-metastatic, castration-resistant prostate cancer (nmCRPC).
- Recent regulatory guidance emphasizes metastasis-free survival as a key endpoint in clinical trials, opening new research avenues.
Discussion:
- Previous therapeutic failures may stem from focusing on tumor shrinkage rather than inhibiting tumor spread.
- Future anti-metastasis drug candidates should be selected based on their anti-migratory potential, not solely anti-proliferative effects.
Key Insights:
- Metastasis-free survival is a critical endpoint for evaluating novel prostate cancer therapies.
- Anti-migratory potential is a more relevant metric for anti-metastasis drug efficacy than anti-proliferative activity.
- Advanced imaging techniques are crucial for monitoring and validating anti-metastasis strategies.
Outlook:
- Oligometastatic cancer models, combined with advanced imaging, can serve as a clinical proof-of-concept for new anti-metastasis therapies.
- This paradigm shift will accelerate the development of more effective treatments for advanced prostate cancer.
Related Concept Videos
Spreading of Chromatin Modifications
Writers
The writer...
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids
Precipitation Titration: Endpoint Detection Methods
In the Volhard method, a standard excess of AgNO3 is first added to the...
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
Molecular and Ionic Solids
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...

